Dermatomiyozit
Özet
Referanslar
Bailey EE, Fiorentino DF. Amyopathic dermatomyositis: definitions, diagnosis, and management. Curr Rheumatol Rep. 2014;16(12):465.
Bitar C, Ninh T, Brag K, et al. Apremilast in Recalcitrant Cutaneous Dermatomyositis: A NONRANDOMIZED CONTROLLED TRIAL. JAMA Dermatol. 2022;158(12):1357–1366.
Cobos GA, Femia A, Vleugels RA. Dermatomyositis: an update on diagnosis and treatment. Am J Clin Dermatol. 2020;21(3):339–353.
DeWane ME, Waldman R, Lu J. Dermatomyositis: clinical features and pathogenesis. J Am Acad Dermatol. 2020;82(2):267–281.
Okiyama N, Fujimoto M. Cutaneous manifestations of dermatomyositis characterized by myositis-specific autoantibodies. F1000Res. 2019;8:F1000 Faculty Rev-1951.
Papadakis MA, McPhee SJ, Rabow MW. Dermatomyositis. In: Current Medical Diagnosis and Treatment 2020, 59th edn, Lange, 2020: 864–867.
Sasaki H, Kohsaka H. Current diagnosis and treatment of polymyositis and dermatomyositis. Mod Rheumatol. 2018;28(6):913–921.
Referanslar
Bailey EE, Fiorentino DF. Amyopathic dermatomyositis: definitions, diagnosis, and management. Curr Rheumatol Rep. 2014;16(12):465.
Bitar C, Ninh T, Brag K, et al. Apremilast in Recalcitrant Cutaneous Dermatomyositis: A NONRANDOMIZED CONTROLLED TRIAL. JAMA Dermatol. 2022;158(12):1357–1366.
Cobos GA, Femia A, Vleugels RA. Dermatomyositis: an update on diagnosis and treatment. Am J Clin Dermatol. 2020;21(3):339–353.
DeWane ME, Waldman R, Lu J. Dermatomyositis: clinical features and pathogenesis. J Am Acad Dermatol. 2020;82(2):267–281.
Okiyama N, Fujimoto M. Cutaneous manifestations of dermatomyositis characterized by myositis-specific autoantibodies. F1000Res. 2019;8:F1000 Faculty Rev-1951.
Papadakis MA, McPhee SJ, Rabow MW. Dermatomyositis. In: Current Medical Diagnosis and Treatment 2020, 59th edn, Lange, 2020: 864–867.
Sasaki H, Kohsaka H. Current diagnosis and treatment of polymyositis and dermatomyositis. Mod Rheumatol. 2018;28(6):913–921.
